BioSpace News Archive

Extendicare Inc. announced that it plans to release its financial results for the third quarter of 2023 after market close on Thursday, November 9, 2023.

Ocuphire Pharma, Inc. today announced presentations featuring results from the ZETA-1 Phase 2 Trial of APX3330 at the 23rd Euretina Congress.

Arcutis Biotherapeutics, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) to expand the indication of ZORYVE (roflumilast) cream 0.3% for the topical treatment of plaque psoriasis.

XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO’s conference call regarding the presentation of the interim report July-September 2023.

Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will present three posters at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held October 13-16, 2023 in Vancouver, BC, Canada.

Marizyme, Inc. (OTCQB:MRZM) (“Marizyme” or the “Company”), a global medical technology company focused on the development of products to address unmet clinical needs, today announced that it was granted a de novo from the U.S. Food and Drug Administration (FDA) for its first in-class product, DuraGraft™.

enVVeno Medical Corporation (Nasdaq:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today announced that it has achieved full enrollment in SAVVE®️, the 75 person U.S. pivotal trial for the VenoValve®️ and the final precursor for seeking FDA pre-market approval of the VenoValve.

Advanced Infusion Care (AIC), a division of AIS Healthcare, today announced its participation in the Immunoglobulin National Society (IgNS) 12th National Conference, which takes place on October 5th – 8th in Denver, Colorado.

Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the grant of inducement awards to three new employees.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that on October 2, 2023, ORIC granted a total of 72,120 non-qualified stock options and 12,040 restricted stock units to four new non-executive employees who began their employment with ORIC in September 2023.